News & Views

A phase 1 trial shows the feasibility of a novel approach combining a powered hip exoskeleton with a passive leg prosthesis to improve the energy efficiency of walking.

Three phase 3 studies show that an immune-checkpoint inhibitor combined with chemotherapy improves progression-free survival in recurrent or metastatic nasopharyngeal cancer.

Machine learning applied to electronic medical records can be used to create personalized lab-test reference ranges and to quantify disease risk, which will pave the way for precision medicine in clinical care.

Cytokine blockade can improve the survival rate of patients with COVID-19 who are at risk of respiratory failure, but timing and patient selection are key.

The first preliminary evidence that in vivo gene editing in a clinical setting is feasible with no early signs of severe adverse events comes from an ongoing clinical trial to treat transthyretin amyloidosis, a fatal monogenetic disease.

Two phase 2 studies of N-terminal tau–targeting antibody therapy fail to show clinical efficacy in progressive supranuclear palsy, despite evidence of target engagement.

A phase 1 trial shows promising anti-tumor activity of tumor-infiltrating-lymphocyte therapy in patients with advanced non–small-cell lung cancer.

A new trial suggests that pirfenidone, an approved treatment for idiopathic pulmonary fibrosis, may also reduce myocardial fibrosis in patients with heart failure who have a preserved left ventricular ejection fraction.

Heterologous dosing with the adenovirus-based ChAdOx1 (AstraZeneca) vaccine followed by an mRNA vaccine induced stronger immune responses than did the homologous ChAdOx1 vaccine series, according to recent immunogenicity studies.

A new study unpacks the complexities of COVID-19 vaccine hesitancy and acceptance across low-, middle- and high-income countries.

Recent studies suggest that neutralizing antibodies could serve as a correlate of protection for vaccines against SARS-CoV-2 in humans.

The first phase 3 trial of amyloid-β-targeting monoclonal antibodies in dominantly inherited Alzheimer’s disease failed to slow cognitive decline in patients. Could it still help to inform future study design and drug development in this setting?

A yeast strain engineered to regulate levels of pathogenic metabolites in the gut provides protection against colitis in mouse models.

Fine-scale population structure can predict complex disease risk within groups better than self-reported race and ethnicity labels.

The first clinical study of an oral small-molecule GLP-1 receptor agonist suggests effective glycemic control and weight loss in patients with type 2 diabetes.

A prospective cohort analysis finds a link between the ChAdOx1 vaccine and an autoimmune disorder known as immune thrombocytopenia—but questions remain and causality is yet to be established.

Clonal hematopoiesis can exist as both a driver and a consequence of inflammatory dysregulation.

A phase 3 study shows that MDMA may be a promising treatment for PTSD, which will require a shift in how this drug is perceived.

New advances in machine learning could facilitate and reduce disparities in the prenatal diagnosis of congenital health disease, the most common and lethal birth defect.

Unexpected clinical results unearth a new facet in CAR design that could facilitate the development of more-effective CAR T cell therapies.